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ABSTRACT: The function of p53 protein, also known as “genome guardian”, might be impaired by the overexpression of its
primary cellular inhibitor, the murine double minute 2 protein (MDM2). However, the recent ﬁnding that MDM2-selective
inhibitors induce high levels of its homologue MDM4, prompt us to identify, through a receptor-based virtual screening on an in
house database, dual MDM2/MDM4 binders. Compound 1 turned out to possess an IC50 of 93.7 and of 4.6 nM on MDM2 and
MDM4, respectively. A series of compounds were synthesized to optimize its activity on MDM2. As a result, compound 12
showed low nanomolar IC50 for both targets. NMR studies conﬁrmed the pocket of binding of 12 as predicted by the Glide
docking software. Notably, 12 was able to cause concentration-dependent inhibition of cell proliferation, yielding an IC50 value of
356 ± 21 nM in neuroblastoma SHSY5Y cells and proved even to eﬃciently block cancer stem cell growth.
■ INTRODUCTION
The tumor suppressor protein p53, commonly referred as
“guardian of the genome”, is one of the most widely studied
regulators of cell fate when the integrity of the genome is
damaged. It is generally activated in response to stress signals
such as oncogene activation or hypoxia and triggers the
expression of downstream targets, thus inducing cellular
apoptosis, senescence, and cell cycle arrest, in order to block
the proliferation of damaged cells.1 The importance of p53
integrity in cancer genesis has been extremely clear when it has
been shown that the TP53 gene is mutated or deleted in nearly
50% of all human tumors and that p53-null mice are prone to
develop spontaneous cancers.2 Although p53 retains wild-type
status in the remaining 50% of human malignancies, its function
might be impaired by multiple mechanisms, where the main
one is mediated by the overexpression of its primary cellular
inhibitor, the murine double minute 2 protein (MDM2).3 In
fact, in physiological conditions, MDM2 and p53 regulate each
other in a feedback mechanism where, upon activation, p53
transcribes MDM2 gene, whose protein binds to p53, thus
hampering p53 binding to targeted DNA. Additionally, MDM2
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causes p53 proteasomal degradation through its E3 ubiquitin
ligase activity and promotes the p53 export out of the cell
nucleus, where it will be no longer accessible to target DNA.4
Deregulation of this autoregulatory loop can provoke malignant
transformation of normal cells. In fact, overexpression of
MDM2 can lead to neutralization of p53 tumor suppressor
function. Accordingly, MDM2 gene ampliﬁcation has been
found in at least 19 tumor types as soft tissue tumors (20%),
osteosarcomas (16%), esophageal carcinomas (13%), and
neuroblastomas, where overexpression of MDM2 correlates
with poor clinical prognosis and poor treatment response to
current cancer therapies.5 Thus, in this scenario, three possible
anticancer therapeutic approaches are viable: (a) the targeting
of mutated p53 through drugs that, acting as chaperones of
mutant p53, restore its function,6 (b) the gene therapy, and (c)
the inhibition of MDM2, which has been the most explored
route in last decades.7 In this regard, the availability of X-ray
crystallographic structural complexes of MDM2 bound to p538
and of MDM2 in complex with p53-mimicking peptides or
nonpeptidic molecules laid the foundation for the design of
high-aﬃnity MDM2 binders.9−18 Notwithstanding, these
substantial advances made in the ﬁeld, Wahl et al. highlighted
how19 MDM2-selective inhibitors may induce high levels of
MDM4, thus aﬀecting the clinical response of these drugs.20 In
fact MDM4, also referred to as MDMX, is the MDM2
homologue and binds to p53 at its transactivation domain,
mainly repressing its transcriptional activity. It is overexpressed
in 18−19% of breast, lung, and colon cancers,21 in 50% of head
and neck squamous carcinomas,22 and in 65% of retinoblasto-
mas.23 To date, a number of biological investigations and
genetic evidence brought to light the importance of reciprocal
levels of MDM2 and MDM4, and it seems that an optimal p53
reactivation and in turn a lasting, eﬀective clinical response can
only be achieved by targeting both MDM proteins simulta-
neously.24 Therefore, the identiﬁcation of high aﬃnity MDM2/
MDM4 inhibitors is an emerging ﬁeld of interest and claims
more eﬀorts for medicinal chemists.25 Recently, attempts to
restore the wild-type p53 tumor suppressor function has been
achieved by interfering with MDM2/MDM4 heterodimeriza-
tion, which is required for an eﬃcient inactivation of p53
function.26 This approach led to a peptide (Pep3), mimicking
the MDM4 C-terminus tail, which has been proved to be
mainly eﬀective toward a speciﬁc subcellular pool of MDM2/
MDM4/p53.26 Diﬀerent complexity is instead posed by the
simultaneous targeting of p53 binding domain of both MDM2
and MDM4. In fact, despite the 50% of amino acids sequence
identity, computational and X-ray studies provided evidence
that these domains in the two MDM proteins are suﬃciently
dissimilar to explain the lack of activity of the MDM2 inhibitors
toward MDM4.27 Nonetheless, the same studies also highlight
that the binding domains of human MDM2 and MDM4 share
some similarities, thus oﬀering promise for the ﬁnding of small-
molecule compounds that can simultaneously target the two
proteins. In fact, several peptide and nonpeptide dual inhibitors
have been recently developed.28−30 However, therapeutic
peptides have well-known drawbacks such as chemical and
physical instability, susceptibility to proteases, and oxidation, so
that organic small molecules are generally preferred. On the
other hand, the organic dual inhibitors reported so far possess
IC50 falling in micromolar range.
31−34 Thus, nowadays, the call
for potent and eﬀective modulators of p53-MDM2/MDM4 is
echoing and fosters the search for new chemical entities.
Comparing the X-ray crystallographic structural complexes of
p53/MDM2 (PDB 1YCR) and p53/MDM4 (PDB 3DAC), it
is evident that the three critical residues of p53 transactivation
domain bind the MDMs N-terminal domains in well-deﬁned
surface pockets characterized by three hydrophobic clefts
hereon named: Phe19, Trp23, and Leu26 pockets. The binding
key residues of p53 interact with L54, L57, I61, M62, Y67, Q72,
V75, F86, F91, V93, H96, I99, Y100, and I103 from MDM2
and interact with M53, L56, I60, M61, Y66, Q71, V74, L85,
F90, V92, P95, L98, Y99, and L102 from MDM4. Nine out of
these 14 residues are completely conserved for both proteins,
therefore clefts at the surface of MDM2 and MDM4 are similar
to each other, a fact that in turn enhances the possibility to ﬁnd
dual inhibitor. As part of our ongoing eﬀorts35 in identifying
novel modulators of p53 pathway, useful against glioblastoma
multiforme (GBM), we here report the identiﬁcation, through a
virtual screening campaign, of a small molecule (1) as dual
MDM2/MDM4 binder and its potent derivative 12, obtained
through a computer-aided optimization step. NMR studies have
been used to conﬁrm the pocket of binding in MDM2. p53
dissociation from MDM2/4 has been quantiﬁed through an
immune-enzymatic assay. The restoration of the p53 pathway
together with the ability of 12 to induce both early and late
apoptosis and to inhibit cancer cell proliferation of diﬀerent
glioblastoma (U87MG) and neuroblastoma (SHSY-5Y) cell
lines and of their stem cells (CSC) subpopulation was assessed.
Notably, 12 was able to cause concentration-dependent
inhibition of cell proliferation, yielding an IC50 value of 356
± 21 nM in neuroblastoma SHSY5Y cells and proved to
eﬃciently block CSC growth.
■ RESULTS AND DISCUSSION
Virtual Screening Campaign. With the aim of ﬁnding
small molecules that can target both MDM proteins
simultaneously, a virtual screening (VS) campaign, by means
of Glide5.5 (Glide, version 5.5; Schrodinger, LLC: New York,
2009) was accomplished. First, we screened an in-house
compound library of ∼4000 small molecules on a MDM2 3D
structure (PDB 3LBL, see Methods section for structure choice
criteria). VS results were then sorted on the basis of the
docking scores, which ranged from −11.083 to −0.681.
Solutions with a docking score higher than the average docking
score calculated for the known active compounds (−6.00) were
discarded (see Methods and Supporting Information, Table SI-
1 for details). On the basis of this criterion, about the 30% of
the entries were retained (825 molecules) and visually
inspected into the MDM2 binding site. Only the molecules
able to occupy at least two of the three MDM2 subpockets
(Leu26, Trp23, and Phe19) have been then used (145 entries)
in a second round of screening against the p53-binding site of
MDM4 (PDB 4N5T). Giving the docking score (−4.017) of
the known selective MDM4 inhibitor 2-[2-chloro-4-[(1,5-
dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)-
methyl]-6-ethoxyphenoxy]-acetic acid methyl ester (SJ-172550,
from now called 1.1),36,37 only the molecules with a docking
score lower than −4.00 were retained (64). Again, the visual
inspection of these best-ranked molecules binding modes took
in consideration the possibility of these ligands to establish
hydrophobic contacts into the three MDM4 subpockets and to
reach the N-terminus region. Only eight compounds were
selected for in vitro tests with the aim to evaluate their ability to
inhibit both MDM2 and MDM4 (see Supporting Information,
Table SI-2 for structures and activities). Seven molecules
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displayed a good inhibitory potency on MDM2 (IC50 in the
nanomolar range); however, only compound 1 proved to
potently induce the dissociation of p53 from MDM4 (IC50 =
4.6 ± 0.7 nM), although it was less eﬀective toward MDM2
(IC50 = 93.7 ± 10.3 nM) (see Biological Evaluation for details).
With these data in hand, we decided to test its synthetic
progenitor, herein named 2, already available in our in-house
database, although not highly ranked in the VS. As a result, 2
displayed a better activity on MDM4 (IC50= 10.4 ± 1.2 nM)
with respect to 1, retaining a fair potency on MDM2 (IC50 =
35.4 ± 3.9 nM, Table 1).
Table 1. Eﬀect of New Compounds on the Dissociation of Human p53/MDM2 or p53/MDM4 Complexa
a1Concentration (nM) leading to half-maximal inhibition of p53/MDM2 complex. 2Concentration (nM) leading to half-maximal inhibition of p53/
MDM4 complex. Data represent the mean values (±SEM) of three independent determinations.
Figure 1. Docking poses of 1 (a) and 2 (b) in MDM2 binding site. 1 and 2 are depicted as golden and coral sticks, respectively. The protein surfaces
are shown as transparent cyan, while the interacting residues are shown as cornﬂower sticks. For clarity reasons, MDM2 binding subpockets are
deﬁned in magenta (Leu 26), blue (Trp 23), and red (Phe 19) dots, respectively (in accordance with the p53 interacting side chains).
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It is worth noticing that these nine selected ligands
demonstrated to be structurally unrelated to the MDM2
ligands described so far. In fact, structural similarities between
the 65 best ranked ligands and known MDM2 inhibitors (taken
from the BindingDB Databank)38 were calculated based upon
JChem ﬁngerprints,39 with the Tanimoto similarity index40
between each hit and the most similar known inhibitor (see
Supporting Information, Table SI-1) ranging from 0.173 to
0.450, indicating that a simple 2D similarity search would not
have allowed to cherry-pick the nine ligands as MDM2
antagonists.
Given these results, a lead optimization campaign was
undertaken simultaneously on 1 and on the more synthetically
accessible 2 in order to improve the activity on MDM2 while
retaining that on MDM4 that was already in a low nanomaolar
range for both hits (IC50= 4.6 ± 0.7 and 10.4 ± 1.2 nM, for 1
and 2, respectively)
Lead Optimization Design toward MDM2. The lead
optimization process was designed by taking into account the
binding poses of 1 and 2 within the MDM2 receptor. As for
compound 1 in MDM2 (Figure 1a), the triphenyl moiety
occupies both the Trp23 and Phe19 lipophilic clefts, while the
third phenyl ring is too far to properly occupy the Leu26
pocket. In addition, from docking results analysis it seems as if
the bulky triphenyl moiety does not allow an accommodation
of the pyridinylaminopropoxy chain into the canonical binding
site, forcing it to ﬂip toward the L2 loop where contacts with
the M62 and E69 side chains could be detected. On the basis of
this observation, compounds 12 and 13 with less bulky groups
were synthesized as ﬁrst derivatives.
Regarding the lead 2, it occupies, similarly to 1, the Trp23
and Phe19 clefts with its triphenyl group, whereas its p-phenol
group can well ﬁt into the N-terminus region establishing
hydrophobic interactions with the Q24, I19, Y100, and M50
side chains and H-bonding the Y100 hydroxyl group, while the
methyl ester can partially occupy the Leu 26 subpocket (1b).
The proper accommodation into the N-terminus region
together with these additional interactions might explain the
better activity of 2 with respect to 1 on MDM2 (2, IC50 = 35.4
nM; 1, IC50 = 93.7 nM).
For 2, which is synthetically more accessible than 1, a series
of analogues with diphenyl moiety instead of the triphenyl one
were designed and, in order to improve the solubility, the
methyl ester was hydrolyzed (3−11). Regarding the central
chain of 2, we tried to invert the chirality of the S-tyrosine
scaﬀold (5). Furthermore, to investigate the eﬀect of diﬀerent
substituents on the phenol ring, involved in both hydrophobic
and polar contacts, we removed the hydroxyl group (6) and
inserted, in position 4, electron-withdrawing (7−8), polar (9),
or alkyl (10−11) groups.
Synthesis. Compounds 4−11 were synthesized in two steps
starting from readily available enantiopure amino acids methyl
ester and phenyl propionic acid derivatives, as shown in
Scheme 1. In a ﬁrst step, the carboxylic acid was activated with
EDC and HOBt in dry chloroform, and the amino acid methyl
ester was added at 0 °C. The reaction was stirred overnight at
room temperature and puriﬁed to give intermediates 2, 3, and
14−22 in good yields (61−98%). The hydrolysis of the ester
function mediated by lithium hydroxide in a mixture of THF/
H2O gave compounds 4−11 with yields ranging from 62 to
97% (see also Table SI-3 in Supporting Information).
Compound 15 has been obtained from its ether precursor 14
by means of triﬂuoroacetic acid promoted cleavage of tert-butyl
group (Scheme 2). Reduction of the nitro-group of compound
17 gave compound 18 in 97% yield (Scheme 3). Compounds 1,
12, and 13 were synthesized from intermediates 2, 3, and 22,
respectively, through a Mitsunobu reaction with intermediate
23, where the pyridine nitrogen has to be protected as N-oxide
(Scheme 4). In the case of triphenylpropionic acid derivative 2,
sonication was needed to accomplish 20% yield of the desired
ether 26. Intermediates 24, 25, and 26 were then reacted with
ammonium formate in order to restore the pyridine nitrogen,
and ﬁnally hydrolysis of the ester function gave compounds 1,
12, and 13 in quite good yields (53−72%). According to
Scheme 5, intermediate 23 was obtained in a four-step synthetic
strategy, starting from 2-bromopyridine and 3-aminopropanol.
After a neat reaction for 12 hours at 150 °C, intermediate 30
was retrieved in 82% yield. The alcohol function was then
protected as tert-butyl-dimethylsilyl (TBDMS) ether 31, and
the pyridine nitrogen was oxidized to N-oxide using meta-
chloroperbenzoic acid (m-CPBA). Finally, TBDMS protection
was cleaved with TBAF to give the desired alcohol intermediate
23 in 76% yield.
Biological Evaluation. MDM2/p53 Complex Dissociation.
The ability of the new synthesized analogues to bind MDM2
was assessed by an immune-enzymatic assay on cell lysates
containing the native p53/MDM2 complex.35 Brieﬂy, in this
Scheme 1. Synthesis of 2-(3-Substituted-propanamido)-3-substitutedpropanoic Acids (4−11)
Scheme 2. Synthesis of (R)-Methyl-2-(3,3-
diphenylpropanamido)-3-(4-hydroxyphenyl)propanoate
(15)
Scheme 3. Synthesis of (S)-Methyl 2-(3,3-
diphenylpropanamido)-3-(4-aminophenyl)propanoate (18)
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b00912
J. Med. Chem. 2017, 60, 8115−8130
8118
assay, cell lysates obtained from U87MG cells were
preincubated for 10 min with the tested compounds and then
incubated on wells precoated with a MDM2 antibody (for
details see Methods section).
The compounds selected from the VS results (see
Supporting Information) showed a moderate aﬃnity toward
MDM2 (Supporting Information, Table 1-SI), with the
exception of N1-[5-chloro-6-methyl-2-(2-pyridyl)pyrimidin-4-
yl]-N2-[6-(triﬂuoromethyl)-2-pyridyl]ethane-1,2-diamine
(RDR03871)41 and our selected lead compounds 1 and 2,
which dissociated the MDM2/p53 with high to very low
nanomolar potencies (IC50 values, Supporting Information,
Table 1-SI and Figure S3). Considering the synthesized
derivatives, compound 5, where the chirality of the S-tyrosine
scaﬀold was inverted (see Supporting Information for docking
results and explanations) and compound 11 showed a very
good inhibitor potency on MDM2 (IC50 = 9.6 and 9.2 nM,
respectively). However, it was the derivative 12 that showed the
higher activity with respect to the leads 1 and 2 (IC50 MDM2 =
7.85 ± 1.07 nM, Figure 2 and Table 1).
MDM4/p53 Complex Dissociation. An immune-enzymatic
assay on SHSY-5Y cell lysates was set up to quantify p53
dissociation from MDM4, retracing the ELISA used for p53/
MDM2.35 Speciﬁc absorbance at 450 nm was found to
proportionally increase with protein concentration of SHSY-
5Y cells (Supporting Information, Figure S1A). Furthermore,
Scheme 4. Synthesis of (S)-2-(3-Substituted-propanamido)-3-(4-(3-(pyridin-2-ylamino)propoxy)phenyl)propanoic Acids (1,
12−13)
Scheme 5. Synthesis of 2-(3-Hydroxypropylamino)pyridine-
1-oxide (23)
Figure 2. Dissociation of human p53/MDMX complex. U87MG (for
p53/MDM2) or SHSY-5Y (for p53/MDM4) cell lysates were
incubated with 12 for 10 min, and the percentage of residual p53/
MDMs complex was quantiﬁed as reported in the Experimental
Section. The data are expressed as a percentage with respect to control
cells (mean ± SEM, N = 3).
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blank samples, obtained in the absence of the primary p53
antibody, were under the 20−25% of total values. To further
validate the assay, the selective MDM4 inhibitor 1.1 and the
MDM2 inhibitor 4-((4R,5S)-4,5-bis(4-chlorophenyl)-2-(2-iso-
propoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-
carbonyl)piperazin-2-one (Nutlin-3, named hereafter 1.2)42,43
were selected as reference compounds (see Chart 1). 1.1
displaced the p53/MDM4 complex, with IC50 value of 847.4 ±
90.8 nM (Supporting Information, Figure SI-1 and Table 1),
comparable to the aﬃnity value reported in literature.36,37 As
expected, 1.2 was not able to completely dissociate p53 from
MDM4 (Supporting Information, Figure S1-B), showing a
maximal percentage of inhibition of 44 ± 2 (Table 1).
Among the compounds selected from the VS, only 1, and
then its progenitor 2 (Table 1), showed a good ability to bind
MDM4, while the others (as reported in Supporting
Information, Table S1) were not able to disrupt signiﬁcantly
the MDM4/p53 complex. Conversely, our synthesized
derivatives dissociated the MDM4/p53 complexes with high
to very low nanomolar potencies (Table 1). In particular,
almost all our derivatives, including compound 5 that showed
good results for MDM2 (see Figure S4 in SI for explanations),
were less potent than the lead compounds, while 12 and 13
showed lower or comparable IC50 values (6.10 ± 0.85 and 3.3
± 0.6 nM, respectively) with respect to 1 and 2. Ultimately,
these preliminary results show that compound 12 presents a
higher activity with respect to the leads 1 and 2 toward both
MDM2 and MDM4 and eﬀectively induces the dissociation of
p53 from MDM2 and MDM4 with comparable potency.
Identiﬁcation of the Binding Site for 12 on MDM2
through NMR Studies. To verify the correctness of the in
silico calculations about the pocket of binding for this series of
compounds on MDM2, an NMR study was performed. We did
not investigate also the MDM4 as we expected similar results.
Thus, regarding the MDM2, the amino acids forming the
binding site for 12 have been identiﬁed by monitoring the
chemical shift perturbation in the 2D 1H−15N HSQC NMR
spectrum of the 15N isotopically enriched protein upon the
addition of increasing amounts of the ligand (Figure 3).44
Aliquots of a DMSO solution of 12 were added to a buﬀered
solution of MDM2 protein at the concentration of 200 μM.
The residues E25, M50, K51, E52, F55, Y56, G58, Q59, I61,
M62, L66, D68, H73, I74, D84, F91, S92, V93, K94, Y100, and
I103 experience the largest chemical shift variation in the
presence of 12 at the theoretical concentration of 400 μM (see
Figure 4a). A comparison between the residues exhibiting the
largest chemical shift perturbations in the presence of 12 and
those resulting from the binding of p53, according to the X-ray
structure of MDM2 with p53 transactivation domain45 clearly
suggest that 12 binds the canonical p53 binding site and no
allosteric pockets are engaged. However, the ligand precip-
itation, observed during the titration, prevents an exact
estimation of its concentration in the buﬀered solution of the
protein and thus of its potency.
Binding Mode of 12 in MDM2 and MDM4. Once NMR
studies unambiguously conﬁrmed that 12 binds the canonical
binding site of p53/MDM2, docking calculations, by means of
Glide5.5 software, were performed to unveil the theoretical
binding mode of 12 to MDM2. Docking calculation on MDM4
protein were also accomplished.
In particular, Figure 5a shows the lowest energy binding pose
found for 12 in MDM2, where the diphenyl moiety occupies
the Phe19 (interacting residues: I61, M62, Y67, V93) and the
Trp23 (interacting residues: L54, L57, F86, F91, I99, I103)
pockets, and the tyrosine central scaﬀold stretches along the α2
helix and establishes van der Waals interactions with the carbon
chains of the K51 and F55 residues. The propoxy-amino linker
interacts with the Q24, I19, M50, and Y100, side chains of the
N-terminus region, while the pyridinyl ring stacks with the H96
within the Leu26 pocket. Clearly, all these interactions
Chart 1. Chemical Structures of the MDM2 and MDM4
Reference Inhibitors
Figure 3. 2D 1H−15N HSQC spectrum of MDM2 (0.2 mM) in the
absence (red) and in the presence (blue) of 12 (0.4 mM).
Figure 4. (a) Chemical shift perturbation (CSP) between the
uninhibited MDM2 (0.2 mM) and MDM2 in the presence of 12
( 0 . 4 mM ) e v a l u a t e d a c c o r d i n g t o t h e f o rm u l a
δ δ δΔ = Δ + Δ1/2 ( /5)H2 N 2 ; the residues exhibiting the largest
CSP are highlighted in red. (b) CSP mapping on the structure of the
protein (PDB 3LBL) in the presence of 12 bound resulting from
docking; the residues with the largest perturbation are highlighted in
red, while 12 is in green.
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endowed 12 with a low nanomolar inhibitory activity toward
MDM2. The fact that the full occupancy of the three binding
clefts (especially Phe19 and Trp23), together with an enlarged
area of hydrophobic interactions, is important to reach a high
inhibitor potency toward this enzyme, is well-known and it is
herein further highlighted by the IC50 values of compounds 11
and 13. In fact, although owing a shorter chain, 11 can still
completely occupy the whole binding site of MDM2, displaying
an IC50 comparable to that of 12, while a lower IC50 is found
for 13 that, possessing an phenyl-ethyl group in place of the
diphenyl one, is no longer able to properly fulﬁll the deep and
hydrophobic Phe19 or the Trp23 subpockets. Notably, the
docking results are in line with the NMR data above-presented.
In fact, as shown in Figure 4b, in the described docking pose,
12 is surrounded by the residues exhibiting the largest CSP.
On the other hand, when 12 is docked into the MDM4
binding site (see Figure 5b) a diﬀerent pose, with respect to
that found in MDM2 is observed. In both receptors the
diphenyl group occupies the Trp23 and the Phe19 subpockets,
but the diﬀerences in the overall shape of the two proteins, with
the MDM4 pocket appearing more compact, makes the central
linker of 12 to arrange diﬀerently. Diﬀerences between the two
proteins also arise in the N-terminus region and especially in
the N-terminal coil conformation. The cleft shape of MDM4
allows the ﬂexible linker of 12 to plunge toward the N-terminus
region so that the central aryl group is sandwiched between the
Y96 phenol and the K51 carbonyl side chain and the amino-
pyridine group H-bonds with the P18 backbone and establishes
hydrophobic contacts with the Q20, V46, and Y96 side chains.
This mode of interaction that stretches all along the enzymatic
cavity evidently is responsible for the low nanomolar activity
toward MDM4. In fact, ligands endowed with diﬀerent core
bulkiness (triphenyl-propanamido, diphenyl-propanamido, phe-
nylbutanamido) but possessing the same long propoxy-amino
linker can be equally accommodated without aﬀecting the
inhibitory potency (1, IC50 = 4.6 nM; 12, IC50 = 6.1 nM; 13,
IC50 = 3.3 nM), while shorter derivatives, such as 11, are no
Figure 5. Docking poses of compound 12 in MDM2 (a) and MDM4 (b) binding sites. The ligand is shown as magenta sticks, the protein surface as
transparent cyan (MDM2) and transparent pale-green (MDM4), while the interacting residues as blue and green sticks, respectively.
Figure 6. Reactivation of p53 pathway. (A,B) SHSY-5Y cells were treated with 12 (1 μM), or the MDM2 inhibitor 1.2 (1 μM), or the MDM4
inhibitor 1.1 (1 μM), alone or in combination, for 24 h. Following treatment, p53 protein expression was evaluated by Western blot analysis, as
reported in the Experimental Section, using GAPDH as the loading control. A representative Western blot (A) and the quantitative analysis of
immunoreactive bands (B) are shown. The data are expressed as the percentage of optical density (OD) versus control (mean ± SEM, N = 2). (C)
The cells were treated as in (A), and mRNA of p53 target genes (MDM2, PUMA, and p21) was quantiﬁed by real-time RT-PCR as reported in the
Experimental Section. The data are expressed as the fold change versus control (mean ± SEM, N = 3). *P < 0.05, **P < 0.01, ***P < 0.001 versus
Control; ## P < 0.01 versus cells treated with 1.2 alone; §§§ P < 0.001 versus cells treated with 1.1 alone.
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longer able to fulﬁll the whole cavity resulting endowed with a
lower IC50.
Noteworthy, it has to be said that although molecular
modeling studies presented herein surely provide explanations
for the ligand activity and are in good accordance with the
NMR data, the ﬂexibility of the N-terminal coil and the poor
amount of information about the N-terminus region especially
regarding the MDM4, make the X-ray crystallography needed
to unambiguously prove these predictions.
Reactivation of the p53 Pathway and Antiproliferative
Activities in Human Neuroblastoma Cells. On the basis of the
results obtained in the immunoenzymatic assay, derivative 12
was used in further assays aimed at exploring the eﬀects of a
cellular treatment with a dual MDM2/4 inhibitor. To this
purpose, human neuroblastoma cells (SHSY-5Y) were chosen
as a representative tumor cell line because they express a wild-
type p53 and present a high expression of MDM2/4.46,47 The
selective MDM4 inhibitor 1.136,37 and the MDM2 inhibitor
1.242,43 were tested in parallel experiments.
First, the reactivation of p53 pathway was assessed by
evaluating transcription induction of p53 target genes and
accumulation of p53 protein.
As expected, 1.2 induced a signiﬁcant accumulation of p53
protein (Figure 6A,B). Similar results were observed with 1.1
(Figure 6A). When cells were incubated with the two drugs, a
signiﬁcant higher p53 accumulation with respect to cells treated
with 1.2 or 1.1 alone (Figure 6A,B) was observed. The dual
inhibitor 12 caused a signiﬁcant enhancement of p53 protein
levels (Figure 6A,B), even greater with respect to that elicited
by the cotreatment 1.1+1.2. This eﬀect may be explained by
considering the aﬃnities of 12 toward MDM2 and MDM4,
which are greater with respect to those elicited by 1.2 and 1.1
toward MDM2 or MDM4, respectively. Anyway, such results
suggest that blocking both MDM2 and MDM4 can induce a
better p53 protein reactivation.
To conﬁrm this, we measured the transcriptional levels of the
following p53 target genes: MDM2, physiological inhibitor of
p53 and its main transcriptional target; PUMA, a gene product
required for p53-mediated apoptosis; p21, a cell cycle
inhibitor.47 Challenging neuroblastoma cells with the MDM2
inhibitor 1.2 for 24 h caused a signiﬁcant induction of MDM2
and p21 (Figure 6C), consistent with the data obtained in
diﬀerent tumor cell lines.43 No signiﬁcant changes were
observed in PUMA mRNA levels (Figure 6C), consistent
with the lack of cellular apoptosis exhibited by 1.2 after 24 h of
cell treatment43 The MDM4 blocker 1.1 signiﬁcantly increased
MDM2 mRNA levels, whereas it did not aﬀect p21 and PUMA
transcription (Figure 6C), thus suggesting that MDM4
inhibition is not enough to fully reactivate p53 transcriptional
activity in the analyzed time of cell treatment. When the two
compounds were combined together, a signiﬁcant increase in
p21 and PUMA transcriptional levels was evidenced with
respect to single-treated cells (Figure 6C). Such results are
consistent with those obtained in Western blotting analysis and
conﬁrm that the combined MDM2/4 inhibition could
reactivate p53 function with an eﬃcacy compared with single
therapy. Compound 12 caused a signiﬁcant enhancement of the
three analyzed p53 target genes (i.e., MDM2, p21 and PUMA),
with greater eﬃcacy with respect to cells incubated with
1.1+1.2 (Figure 6C). These results suggest that the new
compound is able to induce an eﬃcient reactivation of p53
pathway.
Figure 7. Antiproliferative eﬀects of 12 on tumor cells and in their stem cell counterpart. SHSY-5Y (A, B), U87MG (C), or CSCs (D) were
challenged for 24 h (A−C) or 7 days (D) with the indicated concentrations of 12, or 1.2 (1 μM), or 1.1 (1 μM), alone or in combination. Following
incubation, cell proliferation was determined by MTS assay as reported in the Experimental Section. The data are reported as percentage with
respect to control, set to 100% (mean ± SEM, N = 3). A sigmoid dose−response analysis (GraphPad Prism 5 software) was derived in SHSY-5Y
cells (B). **P < 0.01, *** P < 0.001 vs Control; ## P < 0.01 versus cells treated with 1.2 alone; § P < 0.05, §§ P < 0.01 versus cells treated with 1.1
alone.
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Next, the antiproliferative eﬀects of a simultaneous MDM2/4
inhibition were examined by incubating SHSY-5Y cells with the
selected compounds. As depicted in Figure 7A, both 1.2 (1
μM) and 1.1 (1 μM) exhibited a signiﬁcant and comparable
inhibition of neuroblastoma cell proliferation (22.9 ± 1.3 and
23.7 ± 2.6% of inhibition, respectively). When combined
together, the two compounds exhibited a signiﬁcant increase in
their antiproliferative eﬀects (47.1 ± 2.3% of inhibition at 1
μM). Notably, derivative 12, at the same tested concentration
(1 μM), caused an inhibition of cell proliferation of 57.5 ± 2.5
(Figure 7A). The new derivative caused concentration-
dependent eﬀects, yielding an IC50 value of 356 ± 21 nM
(Figure 7B). Altogether, these data demonstrate that the
simultaneous MDM2/4 blocking is able to induce greater
antiproliferative eﬀects in human neuroblastoma cells.
As a comparison, the same experiments were repeated in
human U87MG cells, exhibiting a wild-type p53 but not
overexpressing MDM4.48 In these cells, the MDM4 inhibitor
alone did not aﬀect cell proliferation after 24 h of treatment
(Figure 7C). Conversely, 1.2 and 12 caused a signiﬁcant
inhibition of cell proliferation (Figure 7C). When used
simultaneously, 1.2 was able to sensitize SHSY-5Y to the
MDM4 inhibitor (Figure 7C). Of note, the new derivative was
less eﬃcacious in U87MG cells with respect to SHSY-5Y cells
(30.1 ± 4.4% in U87MG cells). These results are consistent
with the minor MDM4 protein expression of U87MG cells.
To consolidate these data, the eﬀect of the lead compound
was assessed also by Neutral Red Cell Proliferation, which is
based on the ability of viable cells to incorporate and bind the
supravital dye neutral red in the lysosomes.49 As depicted in the
Figure S5 in Supporting Information, compound 12 was
conﬁrmed to inhibit SHSY-5Y and U87MG cell proliferation,
showing comparable percentages of inhibition with respect to
those obtained in the MTS assay.
In addition, preliminary experiments were performed by
isolating the cancer stem cell subpopulation of the tumor cell
lines, which is responsible for cancer recurrence and meta-
stasis.50,51 When CSCs, isolated from U87MG or SHSY-5Y,
were incubated with compound 12 (100 nM−10 μM), a
signiﬁcant and concentration-dependent inhibition of cell
proliferation was evidenced (Figure 7D). The eﬀects elicited
by the new derivative were signiﬁcantly higher in CSCs isolated
from neuroblastoma cells with respect to U87MG cells (% of
inhibition at 100 μM: 78.4 ± 5.9 and 99.2 ± 0.4 in U87MG and
SHSY5Y cells, respectively). These results conﬁrm that
compound 12 is more eﬃcacious in cells overexpressing
MDM4.
Finally, we veriﬁed if the antiproliferative eﬀects of 12 were
associated with cellular apoptosis. Challenging SHSY-5Y with
the new derivative (1 μM) caused a signiﬁcant externalization
of phosphatidylserine, in the absence or in the presence of 7-
amino-actinomycin binding to DNA, thus denoting the
induction of both early and late apoptosis (Figure 8A,B).
■ CONCLUSIONS
The high importance of the impaired functioning of p53 in
human malignancies genesis and progression is still nowadays a
stimulus for ﬁnding eﬀective novel anticancer agents. In this
respect, a number of small-molecule MDM2 inhibitors are
undergoing clinical-stage studies for the treatment of diverse
human cancers. However, it is recently emerging that MDM2-
selective inhibitors may induce high levels of MDM4, thus
aﬀecting the ﬁnal clinical response. Thus, it seems that an
optimal and lasting p53 reactivation can more eﬃciently be
achieved by targeting both MDM proteins simultaneously.
Herein, through a “sequential” virtual screening performed ﬁrst
on MDM2 and then on MDM4, the lead compound 1 was
identiﬁed. It turned out to possess an IC50 of 93.7 and of 4.6
nM on MDM2 and MDM4, respectively. A series of
compounds were synthesized to optimize its activity on
MDM2. As a result, compound 12 showed low nanomolar
IC50 for both targets (IC50 of 7.8 and of 6.1 nM toward MDM2
and MDM4, respectively). Taken together NMR experiments
and molecular docking allow the identiﬁcation of a pocket of
binding in MDM2 and a possible binding mode. Notably, 12
induced a signiﬁcant higher p53 accumulation with respect to
Figure 8. Apoptotic eﬀects of derivative 12. (A,B) SHSY-5Y cells were challenged for 24 h with 1 μM 12. Following treatment, cells were collected
and the percentage of early/late apoptosis was determined as described in the Experimental Section. (A) Representative plots of annexin assay (B)
Quantiﬁcation of annexin staining. The data are reported as the percentage of apoptotic cells versus the total number of cells (mean ± SEM, N = 3).
*** P < 0.001 versus control.
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cells treated with 1.2 or 1.1 alone and with respect to that
elicited by the cotreatment 1.1+1.2. Along the same lines, 12
caused a concentration-dependent inhibition of neuroblastoma
cell proliferation more eﬃciently than both 1.2 and 1.1 alone
and in combination. Notably, 12 showed a signiﬁcant and
concentration-dependent inhibition of CSCs cell proliferation,
isolated from both U87MG and SHSY-5Y. Finally, challenging
SHSY-5Y with 12 (1 μM) a signiﬁcant externalization of
phosphatidylserine was observed, thus denoting the induction
of both early and late apoptosis.
In perfect line with its activity proﬁle, the eﬀects elicited by
the new derivative were signiﬁcantly higher in CSCs isolated
from neuroblastoma cells, overexpressing MDM4, with respect
to U87MG cells. Keeping in mind that the cancer stem cell
(CSCs) subpopulation of the tumor cell lines are responsible
for cancer recurrence and metastasis, the latter data are worthy
of note. All in all, the results herein presented hold new
promises for a better understanding of the structural require-
ments for dual disruptors of MDM2/MDM4/p53 interaction
and for preclinical studies of our compound
■ EXPERIMENTAL SECTION
Virtual Screening. For our study, our in-house database of ∼4000
compounds was used. Such a database was prepared using LigPrep
(LigPrep, version 2.5; Schrödinger, LLC: New York, 2011,) generating
all possible tautomeric, enantiomeric, and protonation states and
keeping only those possessing good ADME properties (calculated by
means of QikProp). The ﬁnal database was composed of 4333
molecules. Compound 12 and 5 were prepared in the same way,
considering all protomeric states.
As per the MDM2 X-ray selection, multiple 3D structures of
MDM2 can be found in the Protein Data Bank (PDB). Among them,
we took into consideration just the ones containing the N-terminus
residues 16−24 (e.g., 3LBL, 4HBM, 4DIJ, 4JVR, 4JVE, 1T4E, 4ERF,
etc.), which folds into an ordered helix that changes shape and size of
the catalytic pocket and provides additional interaction points. So,
among the human nontruncated X-ray structures, only those co-
crystallized with an organic compound were considered and the one
with the highest resolution (1.60 Å) (PDB 3LBL) containing a
spirooxindole derivative was chosen for our Virtual Screening
campaign.
As for the MDM4 X-ray selection, the same criteria were followed.
Only the nontruncated human and humanized X-ray structures were
considered, and among them, the one with the highest resolution (1.70
Å) was chosen (PDB 4N5T). This protein is a humanized zebraﬁsh
MDM4, where the two mutations L46V/V95L were generated by
DNA site-directed mutagenesis in order to make the binding site
identical to that of a human MDM4. The further mutation E20Q,
which is located on the N-terminus region, was manually produced
before preparing the protein for the Virtual Screening campaign. In
this way, the whole cavity of 4N5T, including the N-terminus region,
was identical to that of a human MDM4.
The two proteins were prepared using the Protein Preparation
Wizard implemented in Maestro Suite 2011 (Maestro, version 9.0.211;
Schrodinger, LLC: New York, 2009). During the preparation, all water
molecules were deleted, hydrogen atoms added, and the complex
minimized. The receptor grids were generated using the grid
generation in Glide 5.5 (Glide, version 5.5; Schrodinger, LLC: New
York, 2009.) centered around the crystallized ligand using default
settings. For the VS on the MDM2 structure, the SP mode in Glide
was used ﬁrst, retaining only the best 50% hits that were redocked in
XP mode, letting all other settings at the default. Solutions with a
docking score higher than the average docking score of the known
active compounds (−6.00) were discarded. Structures and inhibition
data for known inhibitors (∼30 hits including compound 1.2) were
downloaded from the BindingDB database.38 The molecules were
prepared using LigPrep, considering all the protonation states, and
were docked with Glide5.5 in XP mode into the MDM2 structure
retaining all the good states. Results ranged from −8.149 to −4.115
with an average −6.132 docking score. Thus, the cutoﬀ for the
screening was set to −6.00. On the basis of this criterion, about the
30% of the entries were retained (825 molecules) and visually
inspected into the MDM2 binding site. The hit compounds chosen
(145 molecules) were then subjected to a second screening on the
MDM4 structure. The SP mode was ﬁrst used retaining the 80% of
compounds (all the good states) that were redocked in the XP mode
and only the molecules with a docking score lower than −4.00 were
retained (64). This cutoﬀ was chosen on the basis of the docking score
of 1.1, which is the MDM4 selective inhibitor used as control in our
assays. Figures 1 and 5 were rendered using PyMOL (www.pymol.
org).
Synthesis. General Methods. Commercially available reagents and
solvents were used without further puriﬁcation. When necessary, the
reactions were performed in oven-dried glassware under a positive
pressure of dry nitrogen. 1H and 13C APT NMR were recorded on a
400 MHz. High-resolution ESI-MS spectra were performed on a
Thermo LTQ Orbitrap XL mass spectrometer. The spectra were
recorded by infusion into the ESI source using MeOH as the solvent.
Chemical shifts (δ) are reported in part per million (ppm) relative to
the residual solvent peak. Column chromatography was performed on
silica gel (70−230 mesh) using the reported eluents. Thin layer
chromatography (TLC) was carried out on 5 cm × 20 cm plates with a
layer thickness of 0.25 mm (Silica gel 60 F254). Purity of tested
compounds was found to be >95% by high performance liquid
chromatography (HPLC). Compounds retention time and purity were
calculated by analytical UHPLC (Shimadzu Nexera liquid chromato-
graph LC-30AD), performed on a C18- bonded Kinetex reverse-phase
column from Phenomenex (2.6 μm, 100 Å, 150 mm × 4.6 mm) with a
ﬂow rate of 1 mL/min and using linear gradients of MeOH (0.1%
TFA) in water (0.1% TFA), from 0 to 90% over 15 min. For
compounds 1, 12, and 13, the analysis was carried out using a gradient
elution of acetonitrile (0.1% TFA) in water (0.1% TFA) from 30 to
70% in 15 min.
General Procedure for the Synthesis of Methyl 2-
Propanamido-3-(phenyl)propanoates (2, 5, 14−22). The
carboxylic acid was dissolved in dry CHCl3 (0.3M) and EDCI·HCl
(1.1 equiv), HOBt (1.2 equiv), and the amino acid methyl ester (1
equiv) were added at 0 °C.52 The reaction was then stirred at room
temperature overnight and monitored by TLC (tipically 7:3 n-hexane/
ethyl acetate). After consumption of the starting materials, the reaction
was diluted with DCM, washed with HCl 1 M (×2), with a saturated
solution of NaHCO3 (×2) and brine. The organic phase was dried
over sodium sulfate and evaporated. The crude mixture was further
puriﬁed over silica gel column (n-hexane/ethyl acetate) to give the
pure products.
General Procedure for the Synthesis of 3-Phenyl-2-
(propanamido)propanoic Acids (6−13). Intermediates 2, 5, and
14−22 were dissolved in a 3:1 mixture of THF/H2O (0.15M), and
lithium hydroxide (2 equiv) was added. The reaction was then stirred
at room temperature overnight and monitored by TLC (typically 7:3
n-hexane/ethyl acetate to monitor starting disappearance). After
consumption of the starting materials, the reaction was diluted with
ethyl acetate and water; the aqueous phase was washed with ethyl
acetate (×2) then acidiﬁed with HCl 1N, and the product was
extracted with ethyl acetate (×3). The organic phase was washed with
brine, dried over sodium sulfate, and evaporated.
Synthesis of (S)-3-(4-(3-(Pyridin-2-ylamino)propoxy)phenyl)-2-
(3,3,3-triphenyl-propanamido)propanoic Acid (1). Intermediate 2
was dissolved in dry THF (0.25M) and triphenylphosphine (1.5
equiv), DIAD (1.4 equiv) and intermediate 23 were added at 0 °C.
The mixture was reacted in an ultrasound bath for 15 min and
monitored by TLC (97:3 DCM/MeOH and 100 μL of TEA). The
crude mixture was evaporated and puriﬁed by column chromatography
to give the product 26 in 20% yield. 26 was dissolved in ethyl acetate
(0.08M), and 10% palladium on charcoal (100 mg per 0.1 mmol) and
ammonium formate (10 equiv) were added at reﬂux temperature. The
reaction was stirred for 30 min, monitored by TLC (ethyl acetate as
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eluent) and ﬁltered through a pad of Celite to give 29 in 90% yield. 29
was then dissolved in a 3:1 mixture of MeOH/H2O (0.25 M), and
lithium hydroxide was added (5 equiv). The reaction was stirred
overnight at room temperature and monitored by TLC (ethyl acetate
as eluent). After consumption of the starting materials, the reaction
was diluted with ethyl acetate and water; the aqueous phase was
washed with ethyl acetate (×2), then neutralized to pH 7 with HCl
1N, and the product was extracted with ethyl acetate (×3). The
organic phase was washed with brine, dried over sodium sulfate, and
evaporated to give 1 in 72% yield. 1H NMR (400 MHz, CD3OD) mix
of rotamers, the main isomer is herein reported: δ 7.87 (br d, 1H),
7.45−7.40 (m, 1H), 7.22−7.11 (m, 15H), 6.89−6.85 (m, 2H), 6.76−
6.73 (m, 2H), 6.57−6.51 (m, 2H), 4.19−4.14 (m, 1H), 4.06 (t, J = 6.0
Hz, 2H), 3.63 (s, 2H), 3.46 (t, J = 6.8 Hz, 2H), 2.89−2.78 (m, 1H),
2.64−2.58 (m, 1H), 2.23 (t, J = 6.4 Hz, 2H). 13C NMR (100 MHz,
CD3OD) δ 174.2, 171.0, 158.7, 157.7, 147.0, 145.8, 138.0, 130.2 (2C),
129.3, 127.6, 125.9, 114.1, 111.9, 108.9, 65.5, 55.9, 38.5, 37.4, 34.9,
29.6, 22.4. tR (min): 12.8. MS (ESI) m/z (M + H)
+ calcd for
C38H38N3O4
+ 600.2857, found 600.2831 [M + H]+.
(S)-Methyl 3-(4-Hydroxyphenyl)-2-(3,3,3-triphenylpropanamido)-
propanoate (2). 1H NMR (400 MHz, CDCl3) δ 7.23−7.15 (m, 15H),
6.66−6.59 (m, 4H), 5.55 (br s, −NH), 4.49−4.45 (m, 1H), 3.60 (dAB J
= 15.04 Hz, 1H), 3.49 (dAB J = 15.04 Hz, 1H), 3.53 (s, 3H), 2.66−2.56
(m, 2H). 13C NMR (100 MHz, CDCl3) δ 171.8, 170.4, 155.5, 146.0,
130.0, 129.1, 128.0, 126.7, 126.3, 115.3, 55.9, 53.5, 52.0, 48.2, 36.8.
Yield: 98%. tR (min): 18.9. MS (ESI) m/z (M + H)
+ calcd for
C31H30NO4
+ 480.2170, found 480.2181 [M + H]+.
(S)-Methyl 2-(3,3-Diphenylpropanamido)-3-(4-hydroxyphenyl)-
propanoate (3). 1H NMR (400 MHz, CDCl3) δ 7.31−7.16 (m,
10H), 6.62 (dAB, J = 8.4 Hz, 2H), 6.57 (dAB, J = 8.4 Hz, 2H), 5.88 (br
d, −NH), 5.79 (br s, −OH), 4.80−4.76 (m, 1H), 4.58 (t, J = 7.92 Hz,
1H), 3.66 (s, 3H), 2.99−2.77 (m, 4H). 13C NMR (100 MHz, CDCl3)
δ 172.1, 171.3, 155.6, 143.4, 143.3, 130.2, 128.7, 128.6, 127.9, 127.6,
126.7 (2C), 126.6, 115.6, 53.34, 52.4, 47.2, 42.8, 37.0. Yield: 95%. tR
(min): 17.0. MS (ESI) m/z (M + H)+ calcd for C25H26NO4
+ 404.1857,
found 404.1860 [M + H]+.
(S)-2-(3,3-Diphenylpropanamido)-3-(4-hydroxyphenyl)propanoic
Acid (4). 1H NMR (400 MHz, CD3OD) δ 7.24−7.12 (m, 10H), 6.83
(d, J = 8.3 Hz, 2H), 6.64 (d, J = 8.3 Hz, 2H), 4.51−4.45 (m, 2H),
3.00−2.85 (m, 3H), 2.79−2.74 (m, 1H). 13C NMR (100 MHz,
CD3OD) δ 173.3, 172.4, 155.8, 143.9, 143.7, 129.8, 128.1, 128.0, 127.5
(2C), 127.4, 126.0, 125.9, 114.8, 53.8, 47.1, 41.5, 36.2. Yield: 87%. tR
(min): 15.0. MS (ESI) m/z (M − H)− calcd for C24H22NO4−
388.1554, found 388.1571 [M − H]−.
(R)-2-(3,3-Diphenylpropanamido)-3-(4-hydroxyphenyl)propanoic
Acid (5). 1H NMR (400 MHz, DMSO-d6) δ 9.20 (br s, −COOH),
8.11 (br d, −NH), 7.24−7.10 (m, 10H), 6.84 (d, J = 8.3 Hz, 2H), 6.60
(d, J = 8.3 Hz, 2H), 4.43−4.39 (m, 1H), 4.27−4.22 (m, 1H), 2.94−
2.77 (m, 3H), 2.68−2.62 (m, 1H). 13C NMR (100 MHz, DMSO-d6) δ
173.4, 170.5, 156.3, 145.0, 144.7, 130.4, 128.7, 128.6, 128.0 (2C),
127.8, 126.3, 115.4, 54.1, 47.0, 49.0, 41.3, 36.6. Yield: 67%. tR (min):
16.6. MS (ESI) m/z (M − H)− calcd for C24H22NO4− 388.1554,
found 388.1569 [M − H]−.
(S)-2-(3,3-Diphenylpropanamido)-3-phenylpropanoic Acid (6).
1H NMR (400 MHz, DMSO-d6) δ 12.70 (br s, −COOH), 8.14 (br
d, −NH), 7.21−7.02 (m, 15H), 4.42−4.38 (m, 1H), 4.32−4.27 (m,
1H), 2.93−2.73 (m, 4H). 13C NMR (100 MHz, DMSO-d6) δ 173.4,
170.4, 145.0, 144.7, 138.1, 129.5, 128.7 (2C), 128.5, 128.0, 127.9,
126.6, 126.4, 54.0, 47.0, 41.2, 37.4. Yield: 92%. tR (min): 18.3. MS
(ESI) m/z (M − H)− calcd for C24H22NO3− 372.1605, found
372.1622 [M − H]−.
(S)-3-(4-Chlorophenyl)-2-(3,3-diphenylpropanamido)propanoic
Acid (7). 1H NMR (400 MHz, DMSO-d6) δ 7.63 (br s, −NH), 7.23−
7.11 (m, 12H), 6.88 (d, J = 7.84 Hz, 2H), 4.44- 4.40 (m, 1H), 4.10−
4.04 (m, 1H), 2.98−2.72 (m, 4H). 13C NMR (100 MHz, DMSO-d6) δ
173.5, 169.9, 145.1, 144.8, 137.8, 131.6, 130.9, 128.7 (2C), 128.1 (2C),
128.0, 126.4, 54.8, 47.1, 41.4, 37.0. Yield: 98%. tR (min): 19.1. MS
(ESI) m/z (M − H)− calcd for C24H21ClNO3− 406.1215, found
406.1216 [M − H]−.
(S)-2-(3,3-Diphenylpropanamido)-3-(4-nitrophenyl)propanoic
Acid (8). 1H NMR (400 MHz, DMSO-d6) δ 12.66 (br s, −COOH),
8.27 (br d, −NH), 8.02 (d, J = 8.80 Hz, 2H), 7.28 (d, J = 8.80 Hz,
2H), 7.22−7.05 (m, 10H), 4.44−4.36 (m, 2H), 3.10−3.05 (m, 1H),
2.92−2.84 (m, 2H), 2.79−2.73 (m, 1H). 13C NMR (100 MHz,
DMSO-d6) δ 172.8, 170.5, 146.6, 146.3, 144.8, 144.6, 130.7, 128.7,
128.6, 128.0, 127.9, 126.5, 126.4, 123.6, 53.0, 46.9, 41.2, 36.9. Yield:
62%. tR (min): 18.1. MS (ESI) m/z (M − H)− calcd for C24H21N2O5−
417.1455, found 417.1459 [M − H]−.
(S)-3-(4-Aminophenyl)-2-(3,3-diphenylpropanamido)propanoic
Acid (9). 1H NMR (400 MHz, DMSO-d6) δ 8.04 (br s, −NH), 7.23−
7.11 (m, 10H), 6.70 (d, J = 8.08 Hz, 2H), 6.41 (d, J = 8.00 Hz, 2H),
4.42−4.38 (m, 1H), 4.21−4.16 (m, 1H), 2.92−2.54 (m, 4H). 13C
NMR (100 MHz, DMSO-d6) δ 173.6, 170.5, 147.4, 145.0, 144.7,
130.0, 128.7, 128.0, 126.4, 124.7, 114.3, 54.3, 47.0, 41.3, 36.7. Yield:
71%. tR (min): 13.5. MS (ESI) m/z (M − H)− calcd for C24H23N2O3−
387.1714, found 387.1709 [M − H]−.
(S)-3-(4-(tert-Butoxy)phenyl)-2-(3,3-diphenylpropanamido)-
propanoic Acid (10). 1H NMR (400 MHz, DMSO-d6) δ 7.73 (br s,
−NH), 7.23−7.11 (m, 10H), 6.84 (d, J = 8.28 Hz, 2H), 6.70 (d, J =
8.24 Hz, 2H), 4.44−4.40 (m, 1H), 4.14−4.10 (m, 1H), 2.97−2.70 (m,
4H), 1.24 (s, 9H). 13C NMR (100 MHz, DMSO-d6) δ 170.0, 153.5,
145.2, 144.8, 133.5, 130.2, 128.7 (2C), 128.1, 128.0, 126.4, 123.5, 77.8,
55.1, 47.0, 41.5, 37.0, 29.0. Yield: 96%. tR (min): 19.2. MS (ESI) m/z
(M − H)− calcd for C28H30NO4− 444.2180, found 444.2173 [M −
H]−.
(S)-3-(4-(Benzyloxy)phenyl)-2-(3,3-diphenylpropanamido)-
propanoic Acid (11). 1H NMR (400 MHz, DMSO-d6) δ 7.43−7.11
(m, 15H), 6.81−6.70 (m, 4H), 5.00 (s, 2H), 4.46−4.42 (m, 1H),
4.06−4.01 (m, 1H), 2.97−2.71 (m, 4H). 13C NMR (100 MHz,
DMSO-d6) δ 169.6, 156.9, 145.3, 144.9, 137.9, 131.3, 130.8, 128.8,
128.7 (2C), 128.2, 128.0 (2C), 126.4 (2C), 114.4, 69.5, 55.5, 47.1,
41.6, 36.8. Yield: 97%. tR (min): 19.9. MS (ESI) m/z (M − H)− calcd
for C31H28NO4
− 478.2023, found 478.2021 [M − H]−.
Synthesis of (S)-2-(3,3-Diphenylpropanamido)-3-(4-(3-(pyridin-2-
ylamino)propoxy) phenyl)propanoic Acid (12). Intermediate 3 was
dissolved in dry THF (0.25M) and triphenylphosphine (1.5 equiv),
DIAD (1.4 equiv), and intermediate 23 were added at 0 °C. The
reaction mixture was then left at room temperature overnight and
monitored by TLC (97:3 DCM/MeOH and 100 μL of TEA). The
crude mixture was evaporated and puriﬁed by column chromatography
to give the product 24 in 67% yield. 24 was dissolved in ethyl acetate
(0.08M), and 10% palladium on charcoal (100 mg per 0.1 mmol) and
ammonium formate (10 equiv) were added at reﬂux temperature. The
reaction was stirred for 30 min, monitored by TLC (ethyl acetate as
eluent), and ﬁltered through a pad of Celite to give 27 in 57% yield. 27
was then dissolved in a 3:1 mixture of MeOH/H2O (0.25M), and
lithium hydroxide was added (5 equiv). The reaction was stirred
overnight at room temperature and monitored by TLC (ethyl acetate
as eluent). After consumption of the starting materials, the reaction
was diluted with ethyl acetate and water; the aqueous phase was
washed with ethyl acetate (×2), then neutralized to pH 7 with HCl
1N, and the product was extracted with ethyl acetate (×3). The
organic phase was washed with brine, dried over sodium sulfate, and
evaporated to give 12 in 67% yield. 1H NMR (400 MHz, CD3OD) δ
7.82 (br d, 1H), 7.61−7.56 (m, 1H), 7.23−7.10 (m, 10H), 6.87 (d, J =
8.40 Hz, 2H), 6.74−6.71 (m, 3H), 6.64 (t, J = 6.20 Hz, 1H), 4.49−
4.42 (m, 2H), 4.04−4.01 (m, 2H), 3.49−3.46 (m, 2H), 2.99−2.77 (m,
4H), 2.09−2.06 (m, 2H). 13C NMR (100 MHz, CD3OD) δ 175.0,
172.2, 157.7, 156.6, 144.2, 144.1, 141.6, 140.2, 130.2, 129.6, 128.3,
128.2, 127.8, 127.6, 126.3, 126.2, 114.4, 111.9, 110.5, 65.1, 55.0, 41.9,
38.7, 36.8, 29.7, 28.6. tR (min): 6.7. MS (ESI) m/z (M + H)
+ calcd for
C32H34N3O4
+ 524.2544, found 524.2581 [M + H]+.
Synthesis of (2S)-2-(3-Phenylbutanamido)-3-(4-(3-(pyridin-2-
ylamino)propoxy)phenyl)-propanoic Acid (13). Intermediate 22
was dissolved in dry THF (0.25M), and triphenylphosphine (1.5
equiv), DIAD (1.4 equiv), and intermediate 23 were added at 0 °C.
The reaction mixture was then left at room temperature overnight and
monitored by TLC (97:3 DCM/MeOH and 100 μL of TEA). The
crude mixture was evaporated and puriﬁed by column chromatography
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to give the product 25 in 20% yield. 25 was dissolved in ethyl acetate
(0.08M), and 10% palladium on charcoal (100 mg per 0.1 mmol) and
ammonium formate (10 equiv) were added at reﬂux temperature. The
reaction was stirred for 30 min, monitored by TLC (ethyl acetate as
eluent), and ﬁltered through a pad of Celite to give 28 in 94% yield. 28
was then dissolved in a 3:1 mixture of MeOH/H2O (0.25M) and
lithium hydroxide was added (5 equiv). The reaction was stirred
overnight at room temperature and monitored by TLC (ethyl acetate
as eluent). After consumption of the starting materials, the reaction
was diluted with ethyl acetate and water; the aqueous phase was
washed with ethyl acetate (×2), then neutralized to pH 7 with HCl 1N
and the product was extracted with ethyl acetate (×3). The organic
phase was washed with brine, dried over sodium sulfate, and
evaporated to give product 13 in 53% yield. 1H NMR (400 MHz,
CD3OD) mix of diasteroisomers, values are reported for one: δ 7.81−
7.79 (m, 1H), 7.63−7.58 (m, 1H), 7.26−7.09 (m, 6H), 6.91 (d, J = 8.4
Hz, 2H), 6.80 (d, J = 8.8 Hz, 2H), 6.67−6.63 (m, 1H), 4.54−4.48 (m,
1H), 4.04−3.99 (m, 2H), 3.46 (t, J = 6.4 Hz, 2H), 3.31−3.29 (m, 1H),
3.17−3.06 (m, 1H), 2.86−2.77 (m, 1H), 2.46−2.35 (m, 2H), 2.09−
2.03 (m, 2H), 1.18 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz,
CD3OD) mix of diasteroisomers, values are reported for one: δ 175.4,
173.0, 157.8, 156.4, 146.2, 141.2, 140.4, 130.2, 130.0, 128.3, 126.7,
126.6, 126.2, 114.2, 111.9, 65.1, 54.9, 44.5, 38.7, 37.1, 36.8, 28.5, 21.0.
tR (min): 8.6. MS (ESI) m/z (M + H)
+ calcd for C27H32N3O4
+
462.2388, found 462.2367 [M + H]+.
Synthesis of (R)-Methyl 2-(3,3-Diphenylpropanamido)-3-(4-
hydroxyphenyl)propanoate (15). Intermediate (R)-methyl 3-(4-
(tert-butoxy)phenyl)-2-(3,3-diphenylpropanamido)propanoate 14 was
dissolved in DCM (0.1M) and triﬂuoroacetic acid (30 equiv) was
added at 0 °C. The reaction mixture was stirred at room temperature
over 2 h. After consumption of 14 as monitored by TLC (7:3 n-
hexane/ethyl acetate), the reaction mixture was neutralized with
potassium carbonate and extracted with ethyl acetate. The organic
layers were then washed with brine, dried over sodium sulfate, and
evaporated to give product 15, which was used for the next step
without further puriﬁcation.
Synthes is of (S ) -Methyl 3- (4-aminopheny l ) -2- (3 ,3-
diphenylpropanamido)propanoate (18). Intermediate (S)-methyl
2-(3,3-diphenylpropanamido)-3-(4-nitrophenyl)propanoate 17 was
dissolved in MeOH (0.1 M), and 10% palladium on charcoal (100
mg per mmol) was added. The reaction mixture was stirred at room
temperature over 5 h in the presence of a balloon of hydrogen. After
consumption of 17 as monitored by TLC (7:3 n-hexane/ethyl acetate;
5:5 n-hexane/ethyl acetate), the reaction mixture was ﬁltered through
a pad of Celite and evaporated to dryness.
Synthesis of 2-((3-Hydroxypropyl)amino)pyridine 1-Oxide (23).
According to a reported procedure,53 2-bromopyridine and 3-amino-1-
propanol (5.5 M) were reacted neat at 150 °C for 12 h in a sealed
tube. The resulting mixture was directly puriﬁed over silica gel (95:5
DCM/MeOH) to give intermediate 30 in 82% yield. 30 was then
dissolved in dry MeCN (0.5 M), and tert-butyl-dimethylsilyl chloride
(1.3 equiv), dimethylaminopyridine (1 equiv), and triethylamine (2.6
equiv) were added at 0 °C. The reaction mixture was then warmed to
room temperature and stirred at 35 °C for 3 h. The crude mixture was
evaporated and puriﬁed by column chromatography to give
intermediate 31 in 95% yield. 31 was dissolved in dry CHCl3 (1
M), and m-chloroperoxybenzoic (1.2 equiv) acid was added.54 The
reaction mixture was stirred at 50 °C for 30 min and puriﬁed by
chromatographic column (95:5 DCM/MeOH, TEA 0.1%) to give 32
in 74% yield. 32 was ﬁnally dissolved in dry THF (0.3M), and a
solution of TBAF in THF (1M) was added (1.1 equiv). The reaction
was stirred at room temperature overnight, evaporated, and puriﬁcated
by chromatographic column to give product 23 in 76% yield.
MDM2 Expression and Puriﬁcation for NMR Measurements.
Escherichia coli BL21-Gold(DE3) cells were transformed with pQE-40
plasmid encoding 6xHis-MDM2 construct. The cells were cultured in
M9 minimal medium supplied with 1.2 g L−1 of (15NH4)2SO4, 3.0 g
L−1 of glucose, and 0.1 mg mL−1 of ampicillin, grown at 310 K, until
A600 nm reached 0.6−0.8, then induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). They were further grown at 310 K for
5 h and then harvested by centrifugation at 7500 rpm for 15 min at
277 K. The pellet was suspended in 50 mM Tris-HCl, pH 8.0, 8 M
GdmCl, 8 mM DTT buﬀer (20 mL per L of culture) and incubated at
277 K overnight upon magnetic stirring. The suspension was
centrifuged at 40000 rpm for 40 min and the pellet discarded. The
recovered supernatant (containing the unfolded protein) was slowly
diluted in 50 mM Tris-HCl, pH 8.0, 500 mM NaCl buﬀer (300 mL
per liter of culture). After 10 min of incubation at 277 K upon
magnetic stirring, 5 mM imidazole were added and the refolded
protein was puriﬁed by nickel ion aﬃnity chromatography using a 5
mL HisTrap HP column. The elution was performed with a linear 0−
500 mM imidazole gradient (5 mL min−1 ﬂow), and the fractions of
puriﬁed protein were identiﬁed by Coomassie staining SDS-PAGE
gels. A further puriﬁcation was carried out by gel ﬁltration using an
HiLoad 26/600 Superdex 75 column in 50 mM KH2PO4, 50 mM
Na2HPO4, pH 7.5, 150 mM NaCl buﬀer (2.5 mL min
−1
ﬂow). Again,
the fractions containing the pure protein were checked by SDS-PAGE,
then joined and concentrated down to the suitable volume.
NMR Measurements. NMR spectra on samples of 15N isotope-
enriched MDM2 protein at the concentration of 0.2 mM in 50 mM
KH2PO4, 50 mM Na2HPO4, pH 7.5, 150 mM NaCl, were acquired at
298 K with a Bruker Avance NMR spectrometer operating at 700
MHz 1H Larmor frequency, equipped with a cryogenically cooled
probe optimized for 13C sensitivity (TCI, S/N 1500:1, on the ASTM
standard sample) as well as for 1H sensitivity. The spectra were
processed with the Bruker TOPSPIN software packages and analyzed
by the program Computer Aided Resonance Assignment (ETH
Zurich; Keller, 2004).
The protein assignment was based on the data reported in the
Biological Magnetic Resonance Data Bank under the accession code
6612 (PMID: 15953616).
Amide NH resonances were detected through 2D 1H−15N
heteronuclear single-quantum correlation (HSQC) experiments,
before and after the addition of increasing concentrations of 12
(0.025, 0.050, 0.100, 0.150, 0.200, 0.250, 0.300, 0.350, 0.400 mM) to
the protein sample. 12 was previously dissolved in dimethyl sulfoxide.
Biological Section. Dissociation Studies of Native MDM2/p53
and MDM4/p53 Complex. The ability of the new derivatives to
dissociate the native p53 from MDM2 or MDM4 was performed by
quantitative sandwich immune-enzymatic assays35 on cell lysates
obtained from U87MG cells (for p53/MDM2) or from SHSY-5Y (for
p53/MDM4). Wells were precoated with full-length anti-MDM2 (sc-
965, Santa Cruz Biotechnology, in 0.05% poly-L-ornithine) or anti-
MDM4 (sc-74468 Santa Cruz Biotechnology, in 0.05% poly-L-
ornithine) antibody overnight at room temperature. The new
compounds were incubated with cell lysates (25 μg) for 10 min at
room temperature and then transferred to the precoated wells for 90
min. After extensive washes, nonspeciﬁc sites were blocked with 1%
BSA, and the wells were incubated for 90 min with a anti-p53 antibody
(sc-6243, Santa Cruz Biotechnology, 1:250). Afterward, samples were
washed and incubated for 60 min with a speciﬁc HRP-conjugate
antibody. The colorimetric quantiﬁcation (450 nm) of the p53/
MDM2 or p53/MDM4 complexes was reached by the addition of a
TMB substrate kit (Thermo Fisher Scientiﬁc). Blanks were in the
absence of the primary anti-p53 antibody and were used to calculate
the nonspeciﬁc binding. Each experiment was performed using 1.2
and/or 1.1 as positive controls. Dose−response curves were derived
with Graph Pad Prism 4 software, from which IC50 values were
obtained.35
Human Cell Lines. Human glioblastoma (U87MG) and human
neuroblastoma (SHSY-5Y) cells were obtained from the National
Institute for Cancer Research of Genoa (Italy). Each cell line was
monitored for DNA proﬁling and cultured as described.43,55
Cancer Stem Cell Isolation. To separate CSCs from each tumor
cell line, 2.5 × 106 cells were cultured in the absence of serum in NSC
medium for 7 days.35,56 Such method was established in our previous
works35,56 and further conﬁrmed by Real Time RT-PCR analysis of
stem cell (CD133, Nestin) and diﬀerentiation markers (GFAP or
NeuN as glial or neuronal marker, respectively), as reported in
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Supporting Information. For the long-term treatment of cells, NSC or
complete medium containing drugs were replaced every 3 days.
Cell Proliferation Assays. U87MG, SHSY-5Y, or the respective
CSCs were incubated with 12 (ranging from 1 nM to 100 μM), or the
MDM2 inhibitor 1.2 (1 μM), or the MDM4 inhibitor 1.1 (1 μM),
alone or in combination, for the indicated times. After the incubation
time, medium-containing drugs was replaced by fresh medium, and
cells were allowed to grow for the indicated days (3 days for GBM
cells, 7 days for GSCs). After treatment period, cell proliferation was
determined using the MTS assay, as described.57
Neutral Cell Assay. Cell proliferation assays were repeated in
U87MG and SHSY-5Y cells by the mean of the Neutral Red staining.49
Brieﬂy, cells were incubated with DMSO (as control) and with
diﬀerent concentrations of 12 (ranging from 1 nM to 100 μM) for 72
h. Following treatments, medium-containing drugs was replaced and
0.33% of Neutral Red solution in an amount equal to 10% of the
culture medium volume was added. The mixture was incubated for 2 h
at 37 °C, and neutral red was removed. The cells were then rinsed with
PBS carefully. Then 100 μL of ethanol/acetic acid (1% glacial acetic
acid, 50% ethanol in PBS) was added to each well. The 96-well plate
was shacked for 10 min to separate neutral red dye from cells and to
make the solution homogeneous. The absorbance of the samples was
measured at 540 nm using a microplate reader.
RNA Extraction and Real-Time PCR Analysis in SHSY-5Y Cells.
SHSY-5Y cells were incubated with 12, 1.2, or 1.1 for 24 h at the
concentration of 1 μM, alone or in combination. Following treatments,
cells were collected, and total RNA was extracted using Rneasy Mini
Kit (Qiagen, Hilden, Germany). cDNA synthesis was performed with
500 ng of RNA (BioRad, Hercules, USA). The mRNA levels of p53
targets (MDM2, PUMA, and p21) were evaluated by quantitative real-
time RT-PCR using Fluocycle II SYBR (Euroclone, Milan, Italy). The
nucleotide sequences, annealing temperature, and product size of the
primers have been previously reported.43,56,58
Western Blotting Analysis. The Western blot analysis was
performed for the evaluation of p53 protein levels. In brief, SHSY-
5Y cells were treated with DMSO (control), with 12 (1 μM), or the
MDM2 inhibitor 1.2 (1 μM), or the MDM4 inhibitor 1.1 (1 μM),
alone or in combination, for 24 h. Following treatments, cells were
collected and lysed by the addition of 200 μL of RIPA buﬀer. Then 40
μL of proteins were diluted in Laemmli solution, resolved by SDS-
PAGE (8.5%), and probed overnight at 4 °C with primary antibody
anti-p53 (sc-6243, Santa Cruz Biotechnology, 1:200). GAPDH was
used as the loading control. ImageJ Software was used for the
densitometric analysis.35
Cellular Apoptosis in SHSY-5Y. SHSY-5Y were treated with DMSO
(control) and 12 (1 μM) for 24 h. Following treatment, living,
apoptotic, and dead cells were collected and analyzed by Muse Cell
Analyzer as described previously.35,57
Statistical Analysis. Graph-Pad Prism (GraphPad Software Inc.,
San Diego, CA) was used for data analysis and graphic presentations.
All data are presented as the mean ± SEM. One-way analysis of
variance (ANOVA) with Bonferroni’s corrected t test for posthoc
pairwise comparisons was used to perform statistical analysis.56,58
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